JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Dual onsets of small cell lung cancer with contrasting neuroendocrine features and immune microenvironments: A case report

  • 0Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan; Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hokkaido, Japan.
Lung +

|

February 7, 2025

|

February 7, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Small cell lung cancer subtypes can change over time. Understanding these shifts is crucial for effective immune checkpoint inhibitor therapy in aggressive lung cancers.

Area Of Science

  • Oncology
  • Immunology
  • Molecular Biology

Background

  • Small cell lung cancer (SCLC) is aggressive with limited treatment options.
  • Immune checkpoint inhibitors (ICIs) show modest benefits, but reliable biomarkers are scarce.
  • SCLC molecular subtypes (SCLC-A, -N, -P, -Y) have different vulnerabilities; SCLC-I responds better to ICIs.

Observation

  • A patient's SCLC transformed from SCLC-I to SCLC-A over three years.
  • The initial SCLC-I subtype showed high CD8+ T-cell infiltration and responded well to atezolizumab.
  • The later SCLC-A subtype had low T-cell infiltration and responded poorly to durvalumab.

Findings

  • SCLC molecular subtypes are dynamic and can change during disease progression.
  • Distinct subtypes exhibit different immune microenvironments and therapeutic responses.
  • Histopathological evaluation is vital for guiding SCLC treatment strategies.

Implications

  • Subtype transitions in SCLC impact immunotherapy effectiveness.
  • Dynamic molecular profiling may be necessary for personalized SCLC treatment.
  • Further research is needed to validate subtype dynamics and develop diagnostic biomarkers.

Keywords: